SCHEMBL3241479

SCHEMBL3241479

COc1cccc(Nc2ncnc3cc(OC)c(O)cc23)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.82
RET P07949 5/20 0.82
SRC P12931 3/20 0.82
RAF1 P04049 5/20 0.74
BRAF P15056 4/20 0.74
KIF5B P33176 2/20 0.69
EPHB2 P29323 2/20 0.69
FGFR1 P11362 1/20 0.69
FLT1 P17948 1/20 0.69
CDK2 P24941 1/20 0.69
PIK3R1 P27986 1/20 0.69
TTBK1 Q5TCY1 1/20 0.69
NOD1 Q9Y239 1/20 0.67
EGFR P00533 8/20 0.66
MAPK14 Q16539 3/20 0.66
ABCG2 Q9UNQ0 2/20 0.66
DYRK3 O43781 1/20 0.66
MAP4K4 O95819 1/20 0.66
PDGFRA P16234 1/20 0.66
LTK P29376 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5474772 0.90 KDR (1.00) KDRRETSRCRAF1KIF5B
Hydrochloric Acid SCHEMBL5483854 0.89 KDR (0.97) KDRRETSRCRAF1KIF5B
SCHEMBL2102382 0.88 EGFR (0.82) KDRRETSRCRAF1BRAF
SCHEMBL5239599 0.88 EGFR (0.80) KDRRETRAF1BRAFKIF5B
SCHEMBL14996742 0.87 EGFR (0.82) KDRRETSRCRAF1BRAF
SCHEMBL4229994 0.87 EGFR (0.82) KDRRETSRCKIF5BEPHB2
SCHEMBL15052373 0.85 BRAF (1.00) RAF1BRAF
SCHEMBL3239025 0.84 EGFR (0.66) KDRRETSRCRAF1BRAF
SCHEMBL644810 0.84 EGFR (0.83) KDRRETSRCRAF1BRAF
SCHEMBL13604745 0.84 EGFR (0.82) KDRRETRAF1BRAFKIF5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1369418-B1 QUINAZOLINE DERIVATIVES MITSUBISHI TANABE PHARMA CORP (JP) 2010-07-28 EP disclosed
US-20070265260-A1 Quinazoline derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-11-15 US disclosed
US-7294629-B2 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-11-13 US disclosed
US-20040116422-A1 Quinazoline derivatives MITSUBISHI PHARMA CORPORATION (JP) 2004-06-17 US disclosed
EP-1369418-A1 QUINAZOLINE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2003-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265260-A1 Quinazoline derivatives TYK2, ROR1, JAK1 KDR 704/4885RET 219/4885SRC 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.